20/20 Biolabs, Inc.
20/20 Biolabs, Inc. scores highest on Earnings (55) and lowest on Nitro (1). Its PosiPenta is 31.05 out of 100, weaker than most similar companies.
On the Penta Grid this week, 20/20 Biolabs, Inc. is Grid #745 of 837 in the Healthcare sector in United States, and Grid #3,558 of 4,000 in United States.
Compared with similar companies in the Healthcare sector in United States.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| 20/20 Biolabs, Inc. | 31.05 | 28 | 55 | 1 | 27 | 44 |
| GRI Bio, Inc. | 31.20 | 48 | 40 | 3 | 50 | 15 |
| 60 Degrees Pharmaceuticals, Inc. | 28.76 | 38 | 29 | 9 | 34 | 35 |
| Adagio Medical Holdings, Inc. | 19.76 | 0 | 37 | 12 | 8 | 42 |
| Ernexa Therapeutics Inc. | 26.84 | 39 | 25 | 5 | 30 | 36 |
| Jupiter Neurosciences, Inc. | 29.17 | 0 | 42 | 7 | 49 | 47 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | -0.35 |
| P/B ratio | 2.05 |
EEarnings
| Trailing EPS | ₹-71.04 |
| Forward EPS | — |
NNitro
| Price | 24.68 |
| 52-week high | 4735.75 |
| 52-week low | 24.68 |
| Fall from 52-week high | 99.5% |
TTorque
| Return on equity (ROE) | -331.22% |
| Debt-to-equity | 0.18 |
AAnchor
| Beta (price swings) | — |
| Market cap | ₹31 Cr |
| Insider holding | 20.40% |
| Dividend yield | 0.00% |
Figures as used for the week of 17 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is 20/20 Biolabs, Inc.'s PosiPenta score?
20/20 Biolabs, Inc.'s PosiPenta is 31.05 out of 100 for the week of 17 Oct 2026, based on 5 of 5 pillars.
Where does 20/20 Biolabs, Inc. stand on the Penta Grid?
On the Penta Grid this week, 20/20 Biolabs, Inc. is Grid #745 of 837 in the Healthcare sector in United States, and Grid #3,558 of 4,000 in United States.
Which PosiPenta pillar is strongest for 20/20 Biolabs, Inc.?
Earnings (growth), with a score of 55 out of 100: around the middle of similar companies.
Which PosiPenta pillar is weakest for 20/20 Biolabs, Inc.?
Nitro (momentum), with a score of 1 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.